Aminodiol HIV protease inhibitors. Synthesis and structure - Activity relationships of P1/P1′ compounds: Correlation between lipophilicity and cytotoxicity

Journal of Medicinal Chemistry

Volumn 39, Issue 10, 1996, Pages 1991-2007

  Chen, Ping ^a   Cheng, Peter T W ^a   Alam, Masud ^a   Beyer, Barbara D ^a   Bisacchi, Gregory S ^a   Dejneka, Tamara ^a   Evans, Adelaide J ^a   Greytok, Jill A ^a   Hermsmeier, Mark A ^a   Humphreys, W Griffith ^a   Jacobs, Glenn A ^a   Kocy, Octavian ^a   Lin, Pin Fang ^a   Lis, Karen A ^a   Marella, Michael A ^a   Ryono, Denis E ^a   Sheaffer, Amy K ^a   Spergel, Steven H ^a   Sun, Chong Qing ^a   Tino, Joseph A ^a   Vite, Gregory ^a   Colonno, Richard J ^a   Zahler, Robert ^a   Barrish, Joel C ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

[1 BENZYL 3 [[3 [(TERT BUTOXYCARBONYL)AMINO] 2 HYDROXY 4 [4 [2 (4 MORPHOLINYL) 2 OXOETHOXY]PHENYL]BUTYL]AMINO] 2 HYDROXYPROPYL]CARBAMIC ACID TERT BUTYL ESTER; [3 [[1 BENZYL 3 [(TERT BUTOXYCARBONYL)AMINO] 2 HYDROXY 4 [4 [2 (3 METHYL 2 OXO 1 IMIDAZOLINYL)ETHOXY]PHENYL]BUTYL]AMINO] 2 HYDROXYPROPYL]CARBAMIC ACID TERT BUTYL ESTER; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOPHILICITY; STRUCTURE ACTIVITY RELATION;

AMINES; CELL DIVISION; CELL LINE; CELL SURVIVAL; HIV PROTEASE INHIBITORS; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0029946713     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm950717a     Document Type: Article

References (51)

1. Darke, P. L.; Nutt, R. F.; Brady, S. F.; Gaesky, V. M.; Cicerone, T.; Leu, C.-T.; Lumma, P. K.; Freidinger, R. M.; Veber, D. F.; Sigal, I. S. HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins. Biochem. Biophys. Res. Commun. 1988, 156, 297-303.
2. (a) Kohl, N. E.; Emini, E. A.; Schleif, W. A.; Davis, L. J.; Heimbach, J. C. for Viral Infectivity. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 4686-4690.
3. (b) Le Grice, S. F.; Mills, J.; Mous, J. Active Site Mutagenesis of the AIDS Virus Protease and its Alleviation by Trans Complementation. EMBO J. 1988, 7, 2547-2553.
4. (c) Peng, C.; Ho, B. K.; Chang, T. W.; Chang, N. T. Role of Human Immunodeficiency Virus Type 1-Specific Protease in Core Protein Maturation and Viral Infectivity. J. Virol. 1989, 63, 2550-2556.
5. (d) Lambert, D. M.; Petteway, S. R.; McDanal, C. E.; Hart, T. K.; Leary, J. J.; Dreyer, B. B., Meek, T. D.; Bugelski, P. J.; Bolognesi, D. P.; Metcalf, B. W.; Matthews, T. J. Human Immunodeficency Virus Type 1 Protease inhibitors irreversibly block Infectivity of Purified Virions from Chronically-infected Cells. Antimicrob. Agents Chemother. 1992, 36, 982-988.
6. (e) Jacobsen, J.; Ahlborn-Laake, L.; Gugel, R.; Mous, J. Progression of Early Steps of Human Protease. J. Virol. 1992, 66, 5087-5091.
7. Reviews: (a) Huff, J. R. HIV Protease: A Novel Chemotherapeutic Target for AIDS. J. Med. Chem. 1991, 34, 2305-2314. (b) Meek, T. D. Inhibition of HIV-1 Protease. J. Enzyme Inhib. 1992, 6, 65-98. (c) Martin, J. A. Recent Advances in the Design of HIV Proteinase Inhibitors. Antiviral Res. 1992, 17, 265-278. (d) Thaisrivongs, S. HIV Protease Inhibitors. Annual Reports in Medicinal Chemistry; Academic Press: San Diego, 1994; Vol. 29, pp 133-134. (e) Barrish, J. C.; Zahler, R. Antiviral Agents. Annual Reports in Medicinal Chemistry; Academic Press: San Diego, 1993; Vol. 28, Chapter 14, pp 131-140. (f) Norbeck, D. W.; Kempf, D. J. HIV Protease Inhibitors. Annual Reports in Medicinal Chemistry; Academic Press: San Diego, 1991; Vol. 26, pp 141-150. (g) Vacca, J. Design of Tight-Binding Human-Immunodeficiency-Virus Type-1 Protease Inhibitors. Methods Enzymol. 1994, 241, 311-334. (h) Kempf, D. Design of Symmetry-Based, Peptidomimetic Inhibitors of Human-Immunodeficiency-Virus Protease. Methods Enzymol. 1994, 241, 334-354.
8. Reviews: (a) Huff, J. R. HIV Protease: A Novel Chemotherapeutic Target for AIDS. J. Med. Chem. 1991, 34, 2305-2314. (b) Meek, T. D. Inhibition of HIV-1 Protease. J. Enzyme Inhib. 1992, 6, 65-98. (c) Martin, J. A. Recent Advances in the Design of HIV Proteinase Inhibitors. Antiviral Res. 1992, 17, 265-278. (d) Thaisrivongs, S. HIV Protease Inhibitors. Annual Reports in Medicinal Chemistry; Academic Press: San Diego, 1994; Vol. 29, pp 133-134. (e) Barrish, J. C.; Zahler, R. Antiviral Agents. Annual Reports in Medicinal Chemistry; Academic Press: San Diego, 1993; Vol. 28, Chapter 14, pp 131-140. (f) Norbeck, D. W.; Kempf, D. J. HIV Protease Inhibitors. Annual Reports in Medicinal Chemistry; Academic Press: San Diego, 1991; Vol. 26, pp 141-150. (g) Vacca, J. Design of Tight-Binding Human-Immunodeficiency-Virus Type-1 Protease Inhibitors. Methods Enzymol. 1994, 241, 311-334. (h) Kempf, D. Design of Symmetry-Based, Peptidomimetic Inhibitors of Human-Immunodeficiency-Virus Protease. Methods Enzymol. 1994, 241, 334-354.
9. Reviews: (a) Huff, J. R. HIV Protease: A Novel Chemotherapeutic Target for AIDS. J. Med. Chem. 1991, 34, 2305-2314. (b) Meek, T. D. Inhibition of HIV-1 Protease. J. Enzyme Inhib. 1992, 6, 65-98. (c) Martin, J. A. Recent Advances in the Design of HIV Proteinase Inhibitors. Antiviral Res. 1992, 17, 265-278. (d) Thaisrivongs, S. HIV Protease Inhibitors. Annual Reports in Medicinal Chemistry; Academic Press: San Diego, 1994; Vol. 29, pp 133-134. (e) Barrish, J. C.; Zahler, R. Antiviral Agents. Annual Reports in Medicinal Chemistry; Academic Press: San Diego, 1993; Vol. 28, Chapter 14, pp 131-140. (f) Norbeck, D. W.; Kempf, D. J. HIV Protease Inhibitors. Annual Reports in Medicinal Chemistry; Academic Press: San Diego, 1991; Vol. 26, pp 141-150. (g) Vacca, J. Design of Tight-Binding Human-Immunodeficiency-Virus Type-1 Protease Inhibitors. Methods Enzymol. 1994, 241, 311-334. (h) Kempf, D. Design of Symmetry-Based, Peptidomimetic Inhibitors of Human-Immunodeficiency-Virus Protease. Methods Enzymol. 1994, 241, 334-354.
10. Reviews: (a) Huff, J. R. HIV Protease: A Novel Chemotherapeutic Target for AIDS. J. Med. Chem. 1991, 34, 2305-2314. (b) Meek, T. D. Inhibition of HIV-1 Protease. J. Enzyme Inhib. 1992, 6, 65-98. (c) Martin, J. A. Recent Advances in the Design of HIV Proteinase Inhibitors. Antiviral Res. 1992, 17, 265-278. (d) Thaisrivongs, S. HIV Protease Inhibitors. Annual Reports in Medicinal Chemistry; Academic Press: San Diego, 1994; Vol. 29, pp 133-134. (e) Barrish, J. C.; Zahler, R. Antiviral Agents. Annual Reports in Medicinal Chemistry; Academic Press: San Diego, 1993; Vol. 28, Chapter 14, pp 131-140. (f) Norbeck, D. W.; Kempf, D. J. HIV Protease Inhibitors. Annual Reports in Medicinal Chemistry; Academic Press: San Diego, 1991; Vol. 26, pp 141-150. (g) Vacca, J. Design of Tight-Binding Human-Immunodeficiency-Virus Type-1 Protease Inhibitors. Methods Enzymol. 1994, 241, 311-334. (h) Kempf, D. Design of Symmetry-Based, Peptidomimetic Inhibitors of Human-Immunodeficiency-Virus Protease. Methods Enzymol. 1994, 241, 334-354.
11. Reviews: (a) Huff, J. R. HIV Protease: A Novel Chemotherapeutic Target for AIDS. J. Med. Chem. 1991, 34, 2305-2314. (b) Meek, T. D. Inhibition of HIV-1 Protease. J. Enzyme Inhib. 1992, 6, 65-98. (c) Martin, J. A. Recent Advances in the Design of HIV Proteinase Inhibitors. Antiviral Res. 1992, 17, 265-278. (d) Thaisrivongs, S. HIV Protease Inhibitors. Annual Reports in Medicinal Chemistry; Academic Press: San Diego, 1994; Vol. 29, pp 133-134. (e) Barrish, J. C.; Zahler, R. Antiviral Agents. Annual Reports in Medicinal Chemistry; Academic Press: San Diego, 1993; Vol. 28, Chapter 14, pp 131-140. (f) Norbeck, D. W.; Kempf, D. J. HIV Protease Inhibitors. Annual Reports in Medicinal Chemistry; Academic Press: San Diego, 1991; Vol. 26, pp 141-150. (g) Vacca, J. Design of Tight-Binding Human-Immunodeficiency-Virus Type-1 Protease Inhibitors. Methods Enzymol. 1994, 241, 311-334. (h) Kempf, D. Design of Symmetry-Based, Peptidomimetic Inhibitors of Human-Immunodeficiency-Virus Protease. Methods Enzymol. 1994, 241, 334-354.
12. Reviews: (a) Huff, J. R. HIV Protease: A Novel Chemotherapeutic Target for AIDS. J. Med. Chem. 1991, 34, 2305-2314. (b) Meek, T. D. Inhibition of HIV-1 Protease. J. Enzyme Inhib. 1992, 6, 65-98. (c) Martin, J. A. Recent Advances in the Design of HIV Proteinase Inhibitors. Antiviral Res. 1992, 17, 265-278. (d) Thaisrivongs, S. HIV Protease Inhibitors. Annual Reports in Medicinal Chemistry; Academic Press: San Diego, 1994; Vol. 29, pp 133-134. (e) Barrish, J. C.; Zahler, R. Antiviral Agents. Annual Reports in Medicinal Chemistry; Academic Press: San Diego, 1993; Vol. 28, Chapter 14, pp 131-140. (f) Norbeck, D. W.; Kempf, D. J. HIV Protease Inhibitors. Annual Reports in Medicinal Chemistry; Academic Press: San Diego, 1991; Vol. 26, pp 141-150. (g) Vacca, J. Design of Tight-Binding Human-Immunodeficiency-Virus Type-1 Protease Inhibitors. Methods Enzymol. 1994, 241, 311-334. (h) Kempf, D. Design of Symmetry-Based, Peptidomimetic Inhibitors of Human-Immunodeficiency-Virus Protease. Methods Enzymol. 1994, 241, 334-354.
13. Reviews: (a) Huff, J. R. HIV Protease: A Novel Chemotherapeutic Target for AIDS. J. Med. Chem. 1991, 34, 2305-2314. (b) Meek, T. D. Inhibition of HIV-1 Protease. J. Enzyme Inhib. 1992, 6, 65-98. (c) Martin, J. A. Recent Advances in the Design of HIV Proteinase Inhibitors. Antiviral Res. 1992, 17, 265-278. (d) Thaisrivongs, S. HIV Protease Inhibitors. Annual Reports in Medicinal Chemistry; Academic Press: San Diego, 1994; Vol. 29, pp 133-134. (e) Barrish, J. C.; Zahler, R. Antiviral Agents. Annual Reports in Medicinal Chemistry; Academic Press: San Diego, 1993; Vol. 28, Chapter 14, pp 131-140. (f) Norbeck, D. W.; Kempf, D. J. HIV Protease Inhibitors. Annual Reports in Medicinal Chemistry; Academic Press: San Diego, 1991; Vol. 26, pp 141-150. (g) Vacca, J. Design of Tight-Binding Human-Immunodeficiency-Virus Type-1 Protease Inhibitors. Methods Enzymol. 1994, 241, 311-334. (h) Kempf, D. Design of Symmetry-Based, Peptidomimetic Inhibitors of Human-Immunodeficiency-Virus Protease. Methods Enzymol. 1994, 241, 334-354.
14. Reviews: (a) Huff, J. R. HIV Protease: A Novel Chemotherapeutic Target for AIDS. J. Med. Chem. 1991, 34, 2305-2314. (b) Meek, T. D. Inhibition of HIV-1 Protease. J. Enzyme Inhib. 1992, 6, 65-98. (c) Martin, J. A. Recent Advances in the Design of HIV Proteinase Inhibitors. Antiviral Res. 1992, 17, 265-278. (d) Thaisrivongs, S. HIV Protease Inhibitors. Annual Reports in Medicinal Chemistry; Academic Press: San Diego, 1994; Vol. 29, pp 133-134. (e) Barrish, J. C.; Zahler, R. Antiviral Agents. Annual Reports in Medicinal Chemistry; Academic Press: San Diego, 1993; Vol. 28, Chapter 14, pp 131-140. (f) Norbeck, D. W.; Kempf, D. J. HIV Protease Inhibitors. Annual Reports in Medicinal Chemistry; Academic Press: San Diego, 1991; Vol. 26, pp 141-150. (g) Vacca, J. Design of Tight-Binding Human-Immunodeficiency-Virus Type-1 Protease Inhibitors. Methods Enzymol. 1994, 241, 311-334. (h) Kempf, D. Design of Symmetry-Based, Peptidomimetic Inhibitors of Human-Immunodeficiency-Virus Protease. Methods Enzymol. 1994, 241, 334-354.
15. (a) Barrish, J. C.; Gordon, E.; Alam, M.; Lin, P.-F.; Bisacchi, G. S.; Chen, P.; Cheng, P. T. W.; Fritz, A. W.; Greytok, J. A.; Hermsmeier, M. A.; Humphreys, W. G.; Lis, K. A.; Marella, M. A.; Merchant, Z.; Mitt, T.; Morrison, R. A.; Obermeier, M. T.; Pluscec, J.; Skoog, M.; Slusarchyk, W. A.; Spergel, S. H.; Stevenson, J. M.; Sun, C.-q.; Sundeen, J. E.; Taunk, P.; Tino, J. A.; Warrack, B. M.; Colonno, R. J.; Zahler, R. Amino diol HIV Protease Inhibitors. 1. Design, Synthesis, and Preliminary SAR. J. Med. Chem. 1994, 37, 1758-1768.
16. (b) Bisacchi, G. S.; Ahmad, S.; Alam, M.; Ashfaq, A.; Barrish, J. C.; Cheng, P. T. W.; Greytok, J.; Hermsmeier, M.; Lin, P.-F.; Merchant, Z.; Skoog, M.; Spergel, S.; Zahler, R. Amino diol HIV Protease Inhibitors. 2. 1,1′-Dimethyl-2-Hydroxyethyl Carbamate Derivatives with Enhanced Potency. Bioorg. Med. Chem. Lett. 1995, 5, 459-464.
17. 95 = 50)
18. 1′ substituent).
19. 1′ Phenol Substituents: X-ray Crystal Structure-Assisted Design. J. Med. Chem. 1992, 35, 1685-1701.
20. 1′ Side Chain on Structure-Activity. J. Med. Chem. 1992, 35, 1702-1709.
21. (a) John, G. W.; Shrivastava, R.; Chevalier, A.; Pognat, J. F.; Massingham, R. An In Vitro Investigation of The Relationships Between Potency, lipophilicity, Cytotoxicity and Chemical Class of Representative Calcium Antagonist Drugs. Pharmacol. Res. 1993, 27, 253-262.
22. (b) Facchetti, I.; Grandi, M.; Cucchi, P.; Geroni, C.; Penco, S.; Vigevani, A. Influence of Lipophilicity on Cytotoxicity of Anthracyclines in LoVo and LoVo/Dx Human Cell Lines. Anti-Cancer Drug Des. 1991, 6, 385-397.
23. (c) Wang, P.-H.; Hui, M. B.; Nandy, P.; Banerjee, S.; Gao, H. K.; Lien, E. Quantitative Structure-Activity Relationship (QSAR) Analysis of the Cytotoxicities of Aminohydroxyguanidine Derivatives and Their Antiviral Activities in vitro. Pharm. Res. 1991, 8, 1006-1012.
24. (d) Hansch, C. Structure-activity Relationships of Chemical Mutagens and Carcinogens. Sci. Total Environ. 1991, 109/ 110, 17-29.
25. (e) Debnath, A. K.; Debnath, G.; Shusterman, A. J.; Hansch, C. A QSAR Investigation of the Role of Hydrophobicity in Regulating Mutagenicity in the Ames Test: 1. Mutagenicity of Aromatic and Heteroaromatic Amines in Salmonella typhimurium TA98 and TA100. Environ. Mol. Mutagenesis 1992, 19, 37-52.
26. L-o-Tyrosine was prepared from the resolution of DL-o-tyrosine; see: Tong, J. H.; Petitclerc, C.; D'Iorio, A.; Benoiton, N. L. Resolution of Ring-Substituted Phenylalanines by the Action of α-Chymotrypsin on their Ethyl Esters. Can. J. Biochem. 1971, 49, 877-881.
27. 2 for 2-6 h. The rate of reaction appears to be dependent on the quality of the catalyst used; the reaction thus needs to be closely monitored. The major side product (usually less than 4%) is the secondary alcohol derived from hydrogenolysis of the epoxide.
28. α Derivatives via Acylamino Malonates. J. Org. Chem. 1973, 38, 457-460.
29. (b) Jackson, R. F. W.; Wishart, N.; Wood, A.; James, K.; Wythes, M. J. Preparation of Enantiomerically Pure Protected 4-Oxo-α-amino Acids and 3-Aryl-α-amino Acids from Serine. J. Org. Chem. 1992, 57, 3397-3404. Sakamoto, H.; Nishimura, S.; Kondo, Y.; Hamanaka, H. Palladium-Catalyzed Coupling Reaction of N-Heteroaryl Halides with Functionalized Alkylzinc Iodides. Synthesis 1988, 485-6.
30. (b) Jackson, R. F. W.; Wishart, N.; Wood, A.; James, K.; Wythes, M. J. Preparation of Enantiomerically Pure Protected 4-Oxo-α-amino Acids and 3-Aryl-α-amino Acids from Serine. J. Org. Chem. 1992, 57, 3397-3404. Sakamoto, H.; Nishimura, S.; Kondo, Y.; Hamanaka, H. Palladium-Catalyzed Coupling Reaction of N-Heteroaryl Halides with Functionalized Alkylzinc Iodides. Synthesis 1988, 485-6.
31. Tilley, J. W.; Sarabu, R.; Wagner, R.; Mulkerina, K. Preparation of Carboalkoxy-alkylphenylalanine Derivatives from Tyrosine. J. Org. Chem. 1990, 55, 906-910.
32. (a) Farina, V.; Krishnan, B. Large Rate Accelerations in the Stille Reaction with Tri-2-furylphosphine and Triphenylarsine as Palladium ligands: Mechanistic and Synthetic Implications. J. Am. Chem. Soc. 1991, 113, 9583-9595.
33. (b) Echavarren, A. M.; Stille, J. K. Palladium-Catalyzed Coupling of Aryl Triflates with Organostannanes. J. Am. Chem. Soc. 1987, 109, 5478-5486.
34. Ghosh, A. K.; Duong, T. T.; McKee, S. P.; Thompson, W. J. N,N′-Disuccinimidyl Carbonate: A Useful Reagent for Alkoxycarbonylation of Amines. Tetrahedron Lett. 1992, 33, 2781-2784.
35. An additional benefit of the increase in polarity is enhanced aqueous solubility. For example, the solubility of 10n at pH 7 is 200 μM compared to 5 μM for the parent compound 1.
36. 1′ phenyl group is exposed to the solvent, thereby allowing substitution at this position. Molecular modeling was performed by attachment of the morpholinamide group to the para position and subsequent geometrical optimization. The atomic positions were fixed to the crystal structure coordinates with the para substituent being allowed to freely move. Several low-energy conformations were found, all of which place the morpholinamide group in the solvent and interacting with surface amino acids (Arg8, Phe53, Pro81, and Val82).
37. Still W. C.; Tempczyk, A.; Hawley, R. C.; Hendrickson, T. Semianalytical Treatment of Solvation for Molecular Mechanics and Dynamics. J. Am. Chem. Soc. 1990, 112, 6127.
38. Weiner, S. J.; Kollman, P. A.; Case, D. A.; Singh, U. C.; Ghio, C.; Alagona, G.; Profeta, S.; Weiner, P. A New Force Field for Molecular Mechanical Simulation of Nucleic Acids and Proteins. J. Am. Chem. Soc. 1984, 106, 765.
39. For a recent example of relating log k′ with log P values, see: Henczi, M.; Nagy, J.; Weaver, D. F. Determination of Octanol-Water Partition Coefficients for a Series of Imidazolidinediones by a Novel Combination of Micro Shake-Flask and HPLC Techniques. J. Liq. Chromatogr. 1994, 17, 2605 and references cited therein.
40. 50 values with theoretical log P values (calculated using the Daylight program) of these analogs (unpublished results, P. Chen, P. T. W. Cheng, and W. G. Humphreys).
41. 50 ratio that this analog does not penetrate cells and therefore its cytotoxicity value would not appear to be meaningful.
42. (a) Ahmad, S.; Ashfaq, A.; Alam, M.; Bisacchi, G. S.; Chen, P.; Cheng, P. T. W.; Greytok, J. A.; Hermsmeier, M. A.; Lin, P.-F.; Lis, K. A.; Merchant, Z.; Mitt, T.; Skoog, M.; Spergel, S. H.; Tino, J. A.; Vite, G. D.; Colonno, R. J.; Zahler, R.; Barrish, J. C. α-Hydroxyamide Derived Amino diols as Potent Inhibitors of HIV Protease. Bioorg. Med. Chem. Lett. 1995, 5, 1729-1734.
43. (b) Gordon, E.; Barrish, J. C.; Bisacchi, G. S.; Sun, C.-q.; Tino, J. A.; Vite, G. D.; Zahler, R. EP 0 580 402 A2.
44. (c) Chen, P.; Cheng, P. T. W.; et. al., unpublished results.
45. (a) Furman, P. A.; McGuirt, P. V.; Keller, P. M.; Fyfe, J. A.; Elion, G. Inhibition by Acyclovir of Cell Growth and DNA Synthesis of Cells Biochemically Transformed with Herpesvirus Genetic Information. Virology 1980, 102, 420-430.
46. (b) Mosmann, T. Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays. J. Immunol. Methods 1983, 65, 55-63.
47. Further characterization of the antiviral properties of compound 10n (BMS-186318) has now been reported: (a) Patick, A. K.; Rose, R.; Greytok, J.; Bechtold, C. M.; Hermsmeier, M. A.; Chen, P.; Barrish, J. C.; Zahler, R.; Colonno, R. J.; Lin, P.-F. Characterization of a Human Immunodeficiency Virus Type 1 Variant with Reduced Sensitivity to an Amino diol Protease Inhibitor. J. Virol. 1995, 69, 2148-2152. (b) Bechtold, C. M.; Patick, A. K.; Alam, M.; Greytok, J.; Tino, J. A.; Chen, P.; Gordon, E.; Ahmad, S.; Barrish, J. C.; Zahler, R.; Lin, P.-F.; Colonno, R. Antimicrob. Agents Chemother. 1995, 39, 374-379.
48. Further characterization of the antiviral properties of compound 10n (BMS-186318) has now been reported: (a) Patick, A. K.; Rose, R.; Greytok, J.; Bechtold, C. M.; Hermsmeier, M. A.; Chen, P.; Barrish, J. C.; Zahler, R.; Colonno, R. J.; Lin, P.-F. Characterization of a Human Immunodeficiency Virus Type 1 Variant with Reduced Sensitivity to an Amino diol Protease Inhibitor. J. Virol. 1995, 69, 2148-2152. (b) Bechtold, C. M.; Patick, A. K.; Alam, M.; Greytok, J.; Tino, J. A.; Chen, P.; Gordon, E.; Ahmad, S.; Barrish, J. C.; Zahler, R.; Lin, P.-F.; Colonno, R. Antimicrob. Agents Chemother. 1995, 39, 374-379.
49. (a) Heimbach, J. C.; Garsky, V. M.; Michelson, S. R.; Dixon, R. A. F.; Sigal, I. S.; Darke, P. L. Affinity Purification of the HIV-1 Protease. Biochem. Biophys. Res. Commun. 1989, 164, 955-960.
50. (b) Weislow, O. S.; Kiser, R.; Fine, D. L.; Bader, J.; Shoemaker, R. H.; Boyd, M. R. New Soluble-Formazan Assay For HIV-1 Cytopathic Effects: Application to High-Flux Screening of Synthetic and Natural Products for AIDS-Antiviral Activity. J. Natl. Cancer Inst. 1989, 81, 577-586.
51. Arnold, H.; Pahls, K.; Potsch, D. Reaktion von N-(Chlorathyl)-2-oxazolidon mit primaren Amien. Tetrahedron Lett. 1969, 137-139.